novavax inc (NVAX) Key Developments
Novavax, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:00 AM
Mar 25 15
Novavax, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.
Novavax Seeks Acquisitions
Mar 24 15
Novavax, Inc. (NasdaqGS:NVAX) intends to use the proceeds for process development expenditures and capital expenditures, as well as acquisitions and other strategic purposes.
Novavax, Inc. Appoints Brian Rosen as Vice President, Government Affairs and Policy
Mar 10 15
Novavax, Inc. announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates. Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide.
Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM
Mar 5 15
Novavax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Russell P Wilson, Senior VP, Business Development.
Novavax, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014
Feb 26 15
Novavax, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $6,724,000 compared to $8,748,000 a year ago. Loss from operations was $31,664,000 compared to $14,253,000 a year ago. Loss from operations before income tax expense was $31,546,000 compared to $14,051,000 a year ago. Net loss was $31,546,000 compared to $14,054,000 a year ago. Basic and diluted net loss per share was $0.13 compared to $0.07 a year ago. The increase in net loss is primarily the result of increased R&D expenses related to the successful RSV F vaccine program and the initiation of 3 RSV clinical trials in the third and fourth quarter of 2014. The 23% decrease in revenue was primarily related to revenues recognized under past agreement for the fourth quarter of 2013 related to the initiation of the Phase II RSV trial in women of childbearing age.
For the full year, the company reported revenue of $30,659,000 compared to $20,915,000 a year ago. Loss from operations was $83,691,000 compared to $52,434,000 a year ago. Loss from operations before income tax expense was $82,947,000 compared to $51,958,000 a year ago. Net loss was $82,947,000 compared to $51,983,000 a year ago. Basic and diluted net loss per share was $0.37 compared to $0.31 a year ago. Net cash used in operating activities was $67.0 million, compared to $45.4 million for 2013. The increase in full year revenue results from the 2014 Phase I/II clinical trial of the H7N9 pandemic vaccine candidate and activities related to the preparation and initiation of the Phase II clinical trial of the quadrivalent seasonal influenza vaccine.